Received Apr 13, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | UNK | LM2221 | IM / RA |
| FLU3 | INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE) | SANOFI PASTEUR | UNK | U8499BA | IM / RA |
| TTOX | TETANUS TOXOID (TEVAX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 235D2 | IM / LA |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | N547S | IM / LA |
Reported Symptoms: 10018767:GULLAIN-BARRE SYNDROME; 10033371:PAIN; 10047862:WEAKNESS; Narrative: This is a 70 year old male with past medical history of dementia, heart failure, osteoarthritis, chronic neuropathic pain, insomnia, chronic bilateral knee pain, lipomas, migraine, PTSD, urinary/bowel incontinence, adjustment disorder with depressed mood, GERD, and dyslipidemia. He received 4 vaccines on 12/18/24 (influenza, COVID-19, Tdap, and Zoster) at his primary care visit. On 12/27/24 his wife reported that he had been experiencing severe whole body pain since the PCP visit, his mobility decreased significantly to the point he was bedbound. Of note was previously on pregabalin 300mg BID and celecoxib 200ng daily for pain, orders were expired at that visit, pregabalin was not renewed until 12/31/24 by the resident physician due to difficulties with controlled substance ordering through system per addendum 12/31/24. The patient presented to ED on 2/27/25 with complain of chronic fatigue and weakness which his wife attributed to the vaccines he received in December 2024. Per ED provider notes, patient reported lower extremity weakness for the past months however no acute symptoms were reported, and CT head scan was negative for acute abnormalities. Provider recommended follow-up with outpatient neurology, per records does not appear patient was seen by neurology provider. Patient continues to be bedbound at baseline as of March 2026. Other Relevant HX: Other: GUILLAIN BARRE, PAIN, WEAKNESS